In 2019, SCHOTT announced a $1 billion investment in its pharmaceutical packaging business to expand capacity by more than 50 percent. Now, SCHOTT has achieved a milestone, delivering vials to three out of every four COVID-19 vaccine projects undergoing phase I, II, and III testing (Source: Global Data). Already, the company has delivered millions of glass vials to SARS-CoV-2 programs including partners of Operation Warp Speed in the U.S.More
SCHOTT supports the world’s fight against COVID-19 with vials capable of holding up to 2 billion vaccination doses. The glassmaker and pharma packaging specialist has reached agreements with leading pharmaceutical companies, including partners of ‘Operation Warp Speed’ – the US government initiative to serve local vaccine production needs. The agreements become effective immediately and first vials are being delivered to companies in North America, Europe and Asia. SCHOTT is ideally positioned to meet the challenging demand situation, as it has been maintaining a global and already validated production network for decades. Even before the expansion, the company already produced more than 11 billion pharma containers for life-saving drugs per annum.More
Global pharma specialist in primary packaging SCHOTT launches a new service for the entire pharmaceutical industry. SCHOTT founded the Pharmaversity, an inspirational network hub for experts in the industry, provided by experts in glass and polymer. This is in line with SCHOTT’s mind-set to strongly focus on collaborative aspects as a key business driver and to share knowledge among the key players in the industry to move it forward together.More
In light of the growing need for pharmaceutical packaging innovations and digitalization, international technology group SCHOTT is introducing Smart Containers. The concept enables industry 4.0 for pharma manufacturers to unlock the power of machine vision and big data analytics on pharmaceutical filling lines. Each SCHOTT Smart Container is laser-marked with a unique identifier to create unprecedented traceability throughout the manufacturing process. The technology can be used to improve reject management and line clearance. Other applications include reducing the risk of mix-up, optimizing lyophilization processes, and supporting container-based targeted recalls.More
The new 2.25mL long syringe was developed for highly viscous biologics, which are administered by use of an autoinjector.
syriQ BioPure® syringes are specifically designed to keep sensitive biologic drugs stable over their shelf life while easing the administration process for patients. The portfolio now includes a new 2.25mL syringe format, which supports both the drug’s and patient’s needs when it comes to administering highly viscous biologics by autoinjector. The new container format will be introduced at Pharmapack trade show in Paris, February 5-6, where SCHOTT is presenting its full range of pharmaceutical containers at booth D60.More
Pharma Packaging division signs exclusive cooperation and development agreement with French engineering company that specializes in developing and manufacturing vision control systems
The international technology group SCHOTT and the French engineering firm SINCAD have signed an exclusive cooperation and development agreement aimed at strengthening SCHOTT’s expertise in the field of camera inspection systems. The agreement includes the assurance that SINCAD will distribute its highly advanced camera systems exclusively to SCHOTT and not offer them to any other supplier in the pharmaceutical industry in the future.More
International technology group SCHOTT is introducing SCHOTT TOPPAC® cosmetic, a new COC (cyclic olefin copolymer) polymer syringe specifically designed for cosmetic and medical applications involving hyaluronic acid. Thanks to a reduced needle pop-off risk, improved dose accuracy and high break resistance, the syringes are especially suitable for highly viscous drugs. The new polymer syringes will become available in February 2019 and will be displayed at IMCAS World Congress in Paris, Jan. 31 to Feb. 2, at TSK Laboratory’s booth #46.More
As the first supplier of nested ready-to-use vials, SCHOTT has expanded its portfolio by large-size ISO formats of 15R, 20R, 25R and 30R vials commercially available for human use (FHU). The vials, which are delivered pre-sterilized in a tub and nest configuration, are manufactured at the company’s production site in USA and are ready to order.More
Global demand for specialized drug delivery devices driving new investments worth several hundred million euros at existing facility in Müllheim, Germany.
Global pharmaceutical systems specialist SCHOTT is again increasing its production capacity for ready-to-use polymer syringes and individualized containers. To meet the high market demand, the company will invest a nine-figure sum to add a new production plant at its existing site in Müllheim, Germany. Construction is scheduled for completion by the end of 2021 with a significant increase in production expected to begin in 2022. The investment also includes a pilot center, allowing for rapid prototyping of packaging innovations.More
SCHOTT AG and Daikyo Seiko Ltd. are announcing that SCHOTT adaptiQ® vials and Daikyo PLASCAP® plastic press-fit closures are confirmed as a Product Set for use with Vanrx Pharmasystems’ Aseptic Filling Workcells.More
Quartz coatings offer utmost protection for highly sensitive drugs / Hydrophobic layers make lyophilization more efficient / New production setup designed to minimize glass-to-glass contact and particle loadMore
SCHOTT AG and ARaymond Life are announcing that SCHOTT adaptiQ® vials and ARaymondlife RayDyLyo® plastic press-fit closures are confirmed as a Product Set for use with Vanrx Pharmasystems’ Aseptic Filling Workcells. This Product Set is fully commercially available and ready-to-use (RTU), with closure integrity performance results available from the suppliers.More